Vox Markets Logo

Open Orphan appoints leading Virology Expert to new advisory board

10:03, 20th February 2020
Abraham Darwyne
Company News
TwitterFacebookLinkedIn

Open Orphan (ORPH) FOLLOW announced on Thursday that it appointed a leading virology expert to its newly established advisory board to guide the company in providing coronavirus solutions.

The specialist pharmaceutical services company focused on orphan drugs and viral vaccine challenge study services, appointed Professor John Oxford and Open Orphan director Professor Brendan Buckley to the Advisory Board.

Open Orphan said the board was established to help it support product development for customers developing antivirals, vaccines and respiratory therapeutics.

The company said it will initially focus on guiding Open Orphan in the provision of solutions to the current Coronavirus outbreak. 

Shares in Open Orphan were trading flat at 5.975p on Thursday after the announcement

ORPH price chart

Open Orphan completed a merger with AIM-listed hVIVO last month to create a European full pharma services company. 

Open Orphan highlighted in a press release that it has Europe's only 24 bedroom quarantine clinic with onsite virology lab in Queen Mary's Hospital London.

Professor John Oxford, who will Chair the Advisory Board, is a Professor at Queen Mary's University London and one of the world's leading experts on global diseases such as influenza, including bird flu, SARS, MERS and Coronavirus.

Professor Buckley is a doctoral graduate in Biochemistry from Oxford University with over 30 years’ experience in clinical research and previously served as Director of the Health Products Regulatory Authority of Ireland.

Follow News & Updates from Open Orphan here: FOLLOW

TwitterFacebookLinkedIn

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Recent Articles
Watchlist